FOR IMMEDIATE RELEASE
Kirkland, QC, September 5th, 2017 — Zoetis announced today the availability of GLANVAC®6, a vaccine for use as an aid in prevention of caseous lymphadenitis (CLA or cheesy gland), enterotoxaemia (pulpy kidney disease), tetanus, black disease, malignant oedema (blackleg like disease) and blackleg in sheep and lambs and swelled head in rams.
“With over 1 million sheep in Canada, it is imperative to provide a vaccine to protect against these common disease causing agents that can have a significant effect on flock health and productivity” comments Dr. Melanie Wowk, Manager Veterinary Services - Cattle/Equine/Genetics Product Support.
Caseous lymphadenitis is a disease often referred to as CLA, or “cheesy gland”. It is an infection primarily of the lymph nodes but it can affect internal organs such as the liver, lung, kidney, and spinal canal. Although abscesses are relatively common in most animal species, they usually occur sporadically, are often confined to individual animals, often occur following a puncture wound or injury, and they can be caused by a variety of bacteria such as streptococci and staphylococci that are common in all environments. Studies report incidence rates of CLA in sheep in Canada and the US ranging from 15 to 94%1,2,3. While incidence rates may vary by region, the disease is prevalent on all continents3. CLA is also a zoonotic disease. CLA is a chronic disease and there is currently no effective treatment.
Prevention through vaccination is the best line of defense against CLA.
“Through a collaborative effort by sheep producer associations, veterinarians, the CFIA Canadian Centre for Veterinary Biologics (CCVB), and Zoetis we were able to bring Glanvac 6 to the Canadian market” comments Toni Bothwell, Director of Regulatory Affairs and Pharmacovigilence at Zoetis Canada Inc. “Zoetis is proud to support the Canadian sheep industry and to build collaborative relationships with multiple industry stakeholders”.
For more information about GLANVAC 6 and its role in flock health, contact your veterinarian and your Zoetis Territory Manager.
Media Contacts: France Lanthier Zoetis
Zoetis (zō-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services.
For more information, visit www.Zoetis.ca
Stanford, K., Brogden, K.A., McClelland, L.A., Kozub, G.C., Audibert,F. The incidence of caseous lymphadenitis in Alberta sheep and assessment of impact by vaccination with commercial and experimental vaccines. Can.J. Vet.Res. 1998; 62(1) 38-43.
Arsenealt, J. et al. Prevalence of and carcass condemnation from maedi–visna, paratuberculosis and caseous lymphadenitis in culled sheep from Quebec, Canada. Preventive Veterinary Medicine 59 (2003) 67–81.
Zoetis® and Glanvac are registered trademarks of Zoetis or its licensors, used under license by Zoetis Canada Inc.
Zoetis Canada Inc. • 16740 Trans-Canada Highway • Kirkland,
QC • H9H 4M7
1-800-663-8888 • www.zoetis.ca